Rocket Pharma director awarded stock and options
Rocket Pharmaceuticals director Carsten Boess reported stock-based awards that increase his equity stake in the company.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Rocket Pharmaceuticals director Carsten Boess reported stock-based awards that increase his equity stake in the company. He received 22,862 restricted stock units that convert into common stock on a one-for-one basis and will vest in full on June 18, 2027. He also received options covering 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027. Following the grant, his direct holdings of common stock total 52,862 shares, with the new option award providing additional potential future ownership.
Insider Trade Summary
Grant/Award: 87,722 shares
Grant/Award
2 txns
Insider
BOESS CARSTEN
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 64,860 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 22,862 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 64,860 contracts (Direct);
Common Stock — 52,862 shares (Direct)
Footnotes (2)
- F1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
- F2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.
Key Figures
RSU grant size: 22,862 shares
Option grant size: 64,860 shares
Option exercise price: $3.35 per share
+3 more
6 metrics
RSU grant size
22,862 shares
Restricted stock units granted to director, vesting June 18, 2027
Option grant size
64,860 shares
Stock options granted to director, underlying common stock
Option exercise price
$3.35 per share
Exercise price for 64,860-share option grant
RSU vesting date
June 18, 2027
Date when 22,862 RSUs vest in full
Option vesting date
June 18, 2027
Date when 64,860 options become fully exercisable
Shares held after award
52,862 shares
Total Rocket Pharmaceuticals common shares held directly after transaction
Key Terms
restricted stock units, RSUs, stock option, exercise price, +1 more
5 terms
restricted stock units financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
stock option financial
"This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "3.3500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vested and exercisable financial
"all of which will become fully vested and exercisable on June 18, 2027."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Rocket Pharmaceuticals (RCKT) director Carsten Boess report?
Carsten Boess reported receiving stock-based compensation awards. He was granted 22,862 restricted stock units and options for 64,860 shares of Rocket Pharmaceuticals common stock, both vesting in full on June 18, 2027, increasing his potential future equity stake.
What are the terms of the Rocket Pharmaceuticals (RCKT) RSU grant to Carsten Boess?
Boess received 22,862 restricted stock units that convert to common stock on a one-for-one basis. According to the filing, these RSUs will vest in full on June 18, 2027, providing him with additional Rocket Pharmaceuticals shares at that time if he remains eligible.
What are the key details of Carsten Boess’s stock option grant at Rocket Pharmaceuticals (RCKT)?
The option grant covers 64,860 shares of common stock with a $3.35 exercise price. All of these options will become fully vested and exercisable on June 18, 2027, giving Boess the right to purchase Rocket Pharmaceuticals shares at that price after vesting.
Does the Rocket Pharmaceuticals (RCKT) Form 4 show any stock sales by Carsten Boess?
The Form 4 shows only acquisitions through stock-based awards, with no reported sales. It records grants of restricted stock units and stock options to Boess, reflecting compensation rather than open-market buying or selling of Rocket Pharmaceuticals shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates